Adipocytes as a source of increased circulating levels of nicotinamide phosphoribosyltransferase/visfatin in active acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 4, 2012, Pages 1355-1362

  Olarescu, Nicoleta C ^a,b   Ueland, Thor ^a   Lekva, Tove ^a   Dahl, Tuva B ^a   Halvorsen, Bente ^a,b   Aukrust, Pål ^a,b   Bollerslev, Jens ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; INTERLEUKIN 6; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;

ACROMEGALY; ADIPOCYTE; ADULT; AGE; ARTICLE; BODY COMPOSITION; BODY FAT; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME INHIBITION; FEMALE; GENDER; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LEAN BODY WEIGHT; LIMB; LIVER CELL; MALE; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; SUBCUTANEOUS ADIPOCYTE; VISCERAL ADIPOCYTE;

ABDOMINAL FAT; ACROMEGALY; ADIPOCYTES, WHITE; ADIPOGENESIS; ADIPOSITY; ADULT; CELL LINE; CELLS, CULTURED; CHEMOKINE CCL2; COHORT STUDIES; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMAN GROWTH HORMONE; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RNA, MESSENGER; SUBCUTANEOUS FAT;

EID: 84859524069     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2417     Document Type: Article

References (40)

1. Ueland T, Fougner SL, Godang K, Lekva T, Schurgers LJ, Scholz H, Halvorsen B, Schreiner T, Aukrust P, Bollerslev J 2010 Associations between body composition, circulating interleukin-1 receptor antagonist, osteocalcin, and insulin metabolism in active acromegaly. J Clin Endocrinol Metab 95:361-368
2. Paisley AN, Banerjee M, Rezai M, Schofield RE, Balakrishnannair S, Herbert A, Lawrance JA, Trainer PJ, Cruickshank JK 2011 Changes in arterial stiffness but not carotid intimal thickness in acromegaly. J Clin Endocrinol Metab 96:1486-1492
3. Berg C, Petersenn S, Lahner H, Herrmann BL, Buchfelder M, Droste M, Stalla GK, Strasburger CJ, Roggenbuck U, Lehmann N, Moebus S, Jöckel KH, Möhlenkamp S, Erbel R, Saller B, Mann K 2010 Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab 95:3648-3656
4. Jayasena CN, Comninos AN, Clarke H, Donaldson M, Meeran K, Dhillo WS 2011 The effects of long-term GH and IGF-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly. Clin Endocrinol (Oxf) 75:220-225
5. Paisley AN, O'Callaghan CJ, Lewandowski KC, Parkinson C, Roberts ME, Drake WM, Monson JP, Trainer PJ, Randeva HS 2006 Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly. J Clin Endocrinol Metab 91:4635-4640 (Pubitemid 44833449)
6. Cannavo S, Almoto B, Cavalli G, Squadrito S, Romanello G, Vigo MT, Fiumara F, Benvenga S, Trimarchi F 2006 Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. J Clin Endocrinol Metab 91:3766-3772 (Pubitemid 44536841)
7. Krusenstjerna-Hafstrøm T, Madsen M, Vendelbo MH, Pedersen SB, Christiansen JS, Møller N, Jessen N, Jørgensen JO 2011 Insulin and GH signaling in human skeletal muscle in vivo following exogenous GH exposure: impact of an oral glucose load. PLoS One 6:e19392
8. Dominici FP, Argentino DP, Muñoz MC, Miquet JG, Sotelo AI, Turyn D 2005 Influence of the crosstalk between growth hormone and insulin signalling on the modulation of insulin sensitivity. Growth Horm IGF Res 15:324-336 (Pubitemid 41403767)
9. Silha JV, Krsek M, Hana V, Marek J, Jezkova J, Weiss V, Murphy LJ 2003 Perturbations in adiponectin, leptin and resistin levels in acromegaly: lack of correlation with insulin resistance. Clin Endocrinol (Oxf) 58:736-742 (Pubitemid 36702734)
10. Sucunza N, Barahona MJ, Resmini E, Fernández-Real JM, Ricart W, Farrerons J, Rodríguez Espinosa J, Marin AM, Puig T, Webb SM 2009 A link between bone mineral density and serum adiponectin and visfatin levels in acromegaly. J Clin Endocrinol Metab 94:3889-3896
11. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I 1994 Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 14:1431-1437
12. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I 2005 Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307:426-430 (Pubitemid 40139988)
13. Garten A, Petzold S, Schuster S, Körner A, Kratzsch J, Kiess W 2011 NAMPT and its potential role in inflammation and type 2 diabetes. Handb Exp Pharmacol 203:147-164
14. Romacho T, Azcutia V, Vázquez-Bella M, Matesanz N, Cercas E, Nevado J, Carraro R, Rodríguez-MañasL, Sánchez-Ferrer CF, PeiróC 2009 Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia 52:2455-2463
15. Dahl TB, Yndestad A, Skjelland M, Øie E, Dahl A, Michelsen A, Damås JK, Tunheim SH, Ueland T, Smith C, Bendz B, Tonstad S, Gullestad L, Frøland SS, Krohg-Sørensen K, Russell D, Aukrust P, Halvorsen B 2007 Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 115:972-980
16. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H 2007 Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178:1748-1758 (Pubitemid 46154646)
17. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S 2000 Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526-529 (Pubitemid 32273628)
18. Ueland T, Fougner SL, Godang K, Schreiner T, Bollerslev J 2006 Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients. Eur J Endocrinol 155:709-715 (Pubitemid 44857495)
19. Ueland T, Lekva T, Otterdal K, Dahl TB, Olarescu NC, Jørgensen AP, Fougner KJ, Brixen K, Aukrust P, Bollerslev J 2011 Increased serum and bone matrix levels of transforming growth factor β1 in patients with growth hormone deficiency in response to growth hormone treatment. Eur J Endocrinol 165:393-400
20. Dahl TB, Haukeland JW, Yndestad A, Ranheim T, Gladhaug IP, Damås JK, Haaland T, Løberg EM, Arntsen B, Birkeland K, Bjøro K, Ulven SM, Konopski Z, Nebb HI, Aukrust P, Halvorsen B 2010 Intracellular nicotinamide phosphoribosyltransferase protects against hepatocyte apoptosis and is down-regulated in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 95:3039-3047
21. Lekva T, Bollerslev J, Kristo C, Olstad OK, Ueland T, Jemtland R 2010 The glucocorticoid-induced leucine zipper gene (GILZ) expression decreases after successful treatment of patients with endogenous Cushing's syndrome and may play a role in glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 95:246-255
22. Friebe D, Neef M, Kratzsch J, Erbs S, Dittrich K, Garten A, Petzold-Quinque S, Blüher S, Reinehr T, Stumvoll M, Blüher M, Kiess W, Körner A 2011 Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia 54:1200-1211
23. Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M 2006 The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 49:1909-1914 (Pubitemid 44025046)
24. Neggers SJ, Kopchick JJ, Jørgensen JO, van der Lely AJ 2011 Hypothesis: extra-hepatic acromegaly: a new paradigm? Eur J Endocrinol 164:11-16
25. Choi KM, Kim JH, Cho GJ, Baik SH, Park HS, Kim SM 2007 Effect of exercise training on plasma visfatin and eotaxin levels. Eur J Endocrinol 157:437-442 (Pubitemid 350018446)
26. Unlütürk U, Harmanci A, Yildiz BO, Bayraktar M 2010 Dynamics of Nampt/visfatin and high molecular weight adiponectin in response to oral glucose load in obese and lean women. Clin Endocrinol (Oxf) 72:469-474
27. Revollo JR, Körner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, Sasaki Y, Wolberger C, Townsend RR, Milbrandt J, Kiess W, Imai S 2007 Nampt/PBEF/Visfatin regulates insulin secretion in β cells as a systemic NAD biosynthetic enzyme. Cell Metab 6:363-375 (Pubitemid 350011996)
28. Imai SI 2011 Dissecting systemic control of metabolism and aging in the NAD world: the importance of SIRT1 and NAMPT-mediated NAD biosynthesis. FEBS Lett 585:1657-1662
29. Bogazzi F, Ultimieri F, Raggi F, Russo D, Manetti L, Cosci C, Sardella C, Costa A, Santini F, Locci T, Bartalena L, Martino E 2007 Abnormal expression of PPAR γ isoforms in the subcutaneous adipose tissue of patients with Cushing's disease. Clin Endocrinol (Oxf) 66:7-12 (Pubitemid 44952488)
30. Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M, Fasshauer M 2005 Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol 185:R1-R8 (Pubitemid 40883404)
31. Wabitsch M, Hauner H, Heinze E, Teller WM 1995 The role of growth hormone/insulin-like growth factors in adipocyte differentiation. Metabolism 44:45-49
32. Luk T, Malam Z, Marshall JC 2008 Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol 83:804-816 (Pubitemid 351959859)
33. Ozkaya M, Sahin M, Cakal E, Yuzbasioglu F, Sezer K, Kilinc M, Imrek SS 2009 Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. J Endocrinol Invest 32:435-439
34. Caixàs A, Tirado R, Vendrell J, Gallart L, Megía A, Simón I, Llauradó G, González-Clemente JM, Giménez-Palop O 2009 Plasma visfatin concentrations increase in both hyper and hypothyroid subjects after normalization of thyroid function and are not related to insulin resistance, anthropometric or inflammatory parameters. Clin Endocrinol (Oxf) 71:733-738
35. Sommer G, Kralisch S, Kloting N, Kamprad M, Schrock K, Kratzsch J, Tonjes A, Lossner U, Bluher M, Stumvoll M, Fasshauer M 2010 Visfatin is a positive regulator of MCP-1 in human adipocytes in vitro and in mice in vivo. Obesity (Silver Spring) 18:1486-1492
36. Sell H, Dietze-Schroeder D, Kaiser U, Eckel J 2006 Monocyte chemotactic protein-1 is a potential player in the negative cross-talk between adipose tissue and skeletal muscle. Endocrinology 147:2458-2467
37. Higashi Y, Sukhanov S, Anwar A, Shai SY, Delafontaine P 2010 IGF-1, oxidative stress and atheroprotection. Trends Endocrinol Metab 21:245-254
38. Fulco M, Cen Y, Zhao P, Hoffman EP, McBurney MW, Sauve AA, Sartorelli V 2008 Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev Cell 14:661-673 (Pubitemid 351622608)
39. Vendelbo MH, Jørgensen JO, Pedersen SB, Gormsen LC, Lund S, Schmitz O, Jessen N, Møller N 2010 Exercise and fasting activate growth hormone-dependent myocellular signal transducer and activator of transcription-5b phosphorylation and insulin-like growth factor-I messenger ribonucleic acid expression in humans. J Clin Endocrinol Metab 95:E64-E68
40. Jackerott M, Møldrup A, Thams P, Galsgaard ED, Knudsen J, Lee YC, Nielsen JH 2006 STAT5 activity in pancreatic β-cells influences the severity of diabetes in animal models of type 1 and 2 diabetes. Diabetes 55:2705-2712 (Pubitemid 44923668)